Drugs / BB-031
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT06226805 | Jul 2024 → Jun 2027 expected | ischemic stroke | Basking Biosciences, Inc. | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT07202663 Background | Nov 2025 → Mar 2026 | — | Basking Biosciences, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-07-30 | Basking Biosciences, Inc. | Results Basking Biosciences Announces Publication Showing BB-031 Restores Blood Flow in a Microfluidic Model of Acute Ischemic Stroke (AIS) baskingbiosciences.com ↗
The study shows that its lead candidate, BB-031, restores blood flow in a microfluidic model of arterial occlusion using blood samples from AIS patients by selectively inhibiting von Willebrand Factor (vWF), a key mediator of clot initiation, growth and stabilization. |
| 2023-05-09 | Basking Biosciences, Inc. | Results Basking Biosciences Presents Novel Reversible RNA-aptamer Thrombolytic at Locus Walk RNA Innovation Conference baskingbiosciences.com ↗
Results of the Phase 1 study showed BB-031 to be safe and well tolerated, with no significant or treatment-emergent adverse events. |
| 2023-02-09 | Basking Biosciences, Inc. | Results Basking Biosciences Presents Positive Clinical Results from Safety and Dose-Escalation Study for First Reversible Thrombolytic Agent at ISC 2023 baskingbiosciences.com ↗
BB-031 demonstrated safety and tolerability following a single intravenous dose ranging from 0.1 mg/kg to 4.0 mg/kg and dose-dependent patterns of vWF binding and changes in platelet function. |
All press releases naming this drug 6 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BB-031 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07202663 ↗ |
| Modality | Aptamer | “RNA aptamer” NCT07202663 ↗ |
| Route | Intravenous | “A single dose of BB-031 will be administered via IV bolus injection” NCT06226805 ↗ |